Literature DB >> 12957752

The relationship between age and production of tumour necrosis factor-alpha in healthy volunteers and patients with chronic heart failure.

Stephan von Haehling1, Sabine Genth-Zotz, Rakesh Sharma, Aidan P Bolger, Wolfram Doehner, Peter J Barnes, Andrew J S Coats, Stefan D Anker.   

Abstract

BACKGROUND: Ageing is associated with an altered immune response. Elevated plasma levels of tumour necrosis factor-alpha (TNF-alpha) are present in patients with advanced chronic heart failure (CHF). However, the relationship between age and the immune response in CHF is unknown.
METHODS: We investigated the relationship between age and the TNF-alpha generating capacity of lipopolysaccharide (LPS) stimulated peripheral blood mononuclear cells (PBMC) in nine healthy control subjects (mean age 51.6+/-3.6 years, age range 39-75 years) and 22 stable patients with CHF (mean age 68.3+/-1.5 years, age range 52-78 years, NYHA class 3.0+/-0.2). We also tested the TNF-alpha generating capacity of all control subjects and 18 CHF patients in whole blood cultures.
RESULTS: Subjects were subgrouped according to baseline TNF-alpha secretion in PBMC cultures into low- and high-responders, with the latter producing TNF-alpha even without LPS stimulation. High-responders produced more TNF-alpha than low-responders at all LPS doses (0.001-10 ng/ml, P<0.0001, repeated measures ANOVA), and high-responders were significantly older than low-responders (controls: 65.8+/-9.2 vs. 47.5+/-2.5 years; patients: 71.9+/-1.9 vs. 65.9+/-1.9 years, both P<0.05). Age correlated with TNF-alpha production in both patients and controls. This effect was independent of NYHA class.
CONCLUSIONS: LPS-responsiveness appears to relate to age in both healthy controls and CHF patients. When assessing the immune status of CHF patients, age should therefore be considered an important confounding factor. In whole blood these findings could only be confirmed at the highest LPS concentration used, thus suggesting that certain factors in the blood may be able to abolish LPS activity at lower concentrations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12957752     DOI: 10.1016/s0167-5273(02)00566-1

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Effects of aging and menopause on serum interleukin-6 levels and peripheral blood mononuclear cell cytokine production in healthy nonobese women.

Authors:  Oh Yoen Kim; Jey Sook Chae; Jean Kyung Paik; Hee Sun Seo; Yangsoo Jang; Jean-Marc Cavaillon; Jong Ho Lee
Journal:  Age (Dordr)       Date:  2011-04-13

2.  Replacing with whole grains and legumes reduces Lp-PLA2 activities in plasma and PBMCs in patients with prediabetes or T2D.

Authors:  Minjoo Kim; Se Ri Jeung; Tae-Sook Jeong; Sang-Hyun Lee; Jong Ho Lee
Journal:  J Lipid Res       Date:  2014-06-05       Impact factor: 5.922

3.  Circulating and PBMC Lp-PLA2 associate differently with oxidative stress and subclinical inflammation in nonobese women (menopausal status).

Authors:  Jean Kyung Paik; Ji Young Kim; Oh Yoen Kim; Yonghee Lee; Tae-Sook Jeong; Gary Sweeney; Yangsoo Jang; Jong Ho Lee
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

4.  Changes in Glucose, TNF-α and IL-6 Blood Levels in Middle-aged Women Associated with Aerobic Exercise and Meditation Training.

Authors:  Sun Hur; Gun-Soo Han; Byung-Jun Cho
Journal:  J Phys Ther Sci       Date:  2014-12-25

Review 5.  Post-infarct remodelling: contribution of wound healing and inflammation.

Authors:  Stefan Frantz; Johann Bauersachs; Georg Ertl
Journal:  Cardiovasc Res       Date:  2008-10-31       Impact factor: 10.787

6.  The relationship between immune status as measured by stimulated ex-vivo tumour necrosis factor alpha levels and the acquisition of nosocomial infections in critically ill mechanically ventilated patients.

Authors:  Gabrielle Levin; J Gordon Boyd; Andrew Day; Miranda Hunt; David M Maslove; Patrick Norman; Nicole O'Callaghan; Stephanie Sibley; John Muscedere
Journal:  Intensive Care Med Exp       Date:  2020-09-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.